Terns Pharmaceuticals Future Growth
Future criteria checks 0/6
Terns Pharmaceuticals's earnings are forecast to decline at 10.1% per annum while its annual revenue is expected to grow at 63.2% per year. EPS is expected to decline by 4.9% per annum. Return on equity is forecast to be -71.6% in 3 years.
Key information
-10.1%
Earnings growth rate
-4.9%
EPS growth rate
| Pharmaceuticals earnings growth | 19.7% |
| Revenue growth rate | 63.2% |
| Future return on equity | -71.6% |
| Analyst coverage | Good |
| Last updated | 21 Jan 2025 |
Recent future growth updates
Recent updates
Terns Pharmaceuticals: Another Potential GLP-1 Entrant
Oct 21Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Sep 25Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
Sep 10We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study
Jun 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 7 | -159 | -107 | N/A | 5 |
| 12/31/2026 | 2 | -142 | -114 | -134 | 6 |
| 12/31/2025 | N/A | -119 | -97 | -103 | 8 |
| 12/31/2024 | N/A | -93 | -87 | -81 | 8 |
| 9/30/2024 | N/A | -88 | -75 | -75 | N/A |
| 6/30/2024 | N/A | -96 | -79 | -79 | N/A |
| 3/31/2024 | N/A | -91 | -76 | -76 | N/A |
| 12/31/2023 | N/A | -90 | -67 | -67 | N/A |
| 9/30/2023 | N/A | -85 | -59 | -59 | N/A |
| 6/30/2023 | N/A | -72 | -52 | -52 | N/A |
| 3/31/2023 | N/A | -68 | -50 | -50 | N/A |
| 12/31/2022 | N/A | -60 | -49 | -49 | N/A |
| 9/30/2022 | 1 | -59 | -49 | -49 | N/A |
| 6/30/2022 | 1 | -54 | -44 | -43 | N/A |
| 3/31/2022 | 1 | -51 | -41 | -41 | N/A |
| 12/31/2021 | 1 | -50 | -42 | -42 | N/A |
| 9/30/2021 | N/A | -35 | -39 | -39 | N/A |
| 6/30/2021 | N/A | -35 | -37 | -37 | N/A |
| 3/31/2021 | N/A | -34 | -37 | -37 | N/A |
| 12/31/2020 | N/A | -29 | -30 | -30 | N/A |
| 9/30/2020 | N/A | -40 | -33 | -32 | N/A |
| 12/31/2019 | N/A | -69 | -67 | -66 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TERN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TERN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TERN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TERN is forecast to have no revenue next year.
High Growth Revenue: TERN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TERN is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 22:19 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Corinne Johnson | Goldman Sachs |
| Corinne Johnson | Goldman Sachs |